A 1st-in-Class, Phase 2 Ready 5-HT3 receptor partial agonist
A 'Software-as-a-Medical-Device' (SaMD) designed to harness the benefits of the 'Clinical Trial Effect' (CTE) in a real world setting
The ClinEffect platform provides a real-world, scalable application of the Clinical Trial Effect, which reduces the expectation of pain (internal prediction)
Meanwhile, the partial agonism of STX-101 reduces pain signaling (sensory observation), leading to reduced pain perception
Copyright © 2024 Serotonix, LLC - All Rights Reserved
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.